Bitcoin ETFs begin trading on Cboe, NYSE Arca and Nasdaq
A number of bitcoin (BTC) exchange-traded funds (ETFs) have begun trading shares on exchanges following the January 10 approval by the United States Securities and Exchange Commission.
As of January 11 at 2:45 PM UTC, data from the Cboe BZX exchange showed that the Bitcoin ETF was trading below ARK 21Shares at $50.18 per ticker ARKB, Invesco Galaxy at BTCO at $49.59, WisdomTree at $52.13. BTCW, Fidelity at $44.40 under FBTC, and Franklin Temple at $28.48 under EZBC. The spot BTC ETF offered by VanEck does not seem to be under the ticker HODL, but settled for an opening price of $54.92.
On the Nasdaq stock market, shares of the Valkyrie Bitcoin Fund under the ticker symbol BRRR started trading around $20 in premarket trading before falling to $14.10 by the time of publication. Shares of iShares Bitcoin Trust – the world's largest asset manager BlackRock – rose roughly 22% in some pre-market activity under IBIT, trading at $28.64 at press time.
Related: Priced in or not? BTC Miners and Traders Prepare for Bitcoin ETF Trading
The Spot Bitcoin ETF offered by Grayscale Investments – one of the offerings that contributed to the SEC approval of investment vehicles – opened at $42.25 under GBTC on the New York Stock Exchange Arca, rising to $42.97 at the time of publication. Shares of Bitwise Bitcoin Trust started trading at $26.80 under BITB, while Hashdex Bitcoin Futures ETF, which holds the position following SEC approval, opened at $60.00 under ticker DEFI.
Watch the world live trading #Bitcoin ETF news. pic.twitter.com/k8gzzoXPHH
— _Checkmatey ⚡☢️️ (@_Checkmatey_) January 10, 2024
Cboe's BZX exchange approved listings for the Bitcoin ETF on January 11 ahead of any word from the SEC, which later issued letters saying the exchange had been approved. The SEC later published a notice announcing full regulatory approval for spot BTC ETFs from 11 asset managers on Nasdaq, Cboe BZX and NYSE Arca.
Magazine: How to protect your crypto in a volatile market: Bitcoin OGs and experts weigh in.
